AC Immune Down; Semorinemab Didn't Meet Efficacy Endpoint in Early Alzheimer's Disease
23 Septembre 2020 - 3:23PM
Dow Jones News
By Michael Dabaie
AC Immune SA shares fell 43% to $4.94 in premarket trading.
The company said a Phase 2 trial of semorinemab didn't meet the
co-primary efficacy endpoint or two secondary endpoints for early
Alzheimer's disease. Swiss-based clinical-stage biopharmaceutical
company AC Immune said its partner, Roche Group's Genentech,
informed the company of the top-line results of the trial, which
showed semorinemab didn't meet its co-primary goal of reducing the
decline on Clinical Dementia Rating-Sum of Boxes compared to a
placebo.
The secondary endpoints of Alzheimer's Disease Assessment
Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative
Study Group--Activities of Daily Living Inventory also weren't met,
AC Immune said.
The company said additional data analyses are ongoing and
Genentech plans to present the results from the trial at an
upcoming medical congress. The second Phase 2 study of semorinemab
in patients with moderate Alzheimer's disease remains ongoing, the
company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 23, 2020 09:08 ET (13:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AC Immune (NASDAQ:ACIU)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
AC Immune (NASDAQ:ACIU)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
